Guangdong Vtr Bio-Tech Co., Ltd. Class A

Guangdong Vtr Bio-Tech Co., Ltd. Class A

SSZSE:300381
5.30
CNY
-0.18
(-3.28%)
-0.07EPS
2.73BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.54
1.32
2.29
3.94
3.69
4.35
4.91
4.11
3.86
2.4
1.62
1.68
1.7
1.71
Basic EPS, GAAP
0.27
0.2
0.23
0.3
0.2
0.28
0.31
0.35
-0.24
0.04
-0.02
0.06
-0.04
-0.07
Free Cash Flow per Basic Share
0.04
-0.13
-0.14
-1
-0.87
-0.26
0.11
0.26
0.11
0.11
-0.49
-0.63
-0.32
- -
Dividend per Share
- -
0.08
0.1
0.14
0.17
0.25
0.17
0.14
0.14
0.13
0.1
0.07
0.1
0.01
Book Value per Share
1.3
2.41
3.6
4.67
4.77
5.27
5.6
6.08
5.7
5.52
5.33
5.32
5.19
5.27
Tangible Book Value per Share
1.26
1.78
1.78
2.93
2.76
3.21
3.69
4.32
4.03
4.91
4.6
4.59
4.44
4.57
Basic Weighted Avg Shares
234
272
307
384
407
407
418
466
490
490
491
490
491
483
Sales/Revenue/Turnover
359
360
703
1,512
1,499
1,768
2,048
1,915
1,892
1,174
796
826
832
827
Operating Margin (%)
19.37
17.39
13.46
12.8
15.21
15.52
13.44
16.56
6.72
-4.97
-2.72
2.02
0.01
-1.33
Depreciation Expense
10
14
38
92
106
124
153
155
168
138
112
113
129
- -
Net Income, GAAP
63
55
72
114
80
114
128
162
-119
18
-11
31
-20
-34
Effective Tax Rate (%)
14.4
13.4
14.6
8.4
15.6
15.77
11.16
12.78
- -
64.29
9.92
- -
- -
- -
Profit Margin (%)
17.58
15.32
10.21
7.51
5.36
6.42
6.23
8.45
-6.28
1.55
-1.35
3.76
-2.38
-4.14
Working Capital
142
315
177
547
331
1,144
927
938
785
1,794
1,386
1,041
829
808
LT Debt
- -
90
161
206
146
727
486
119
127
51
- -
- -
- -
- -
Total Equity
306
685
1,416
2,055
2,090
2,407
2,729
3,263
3,048
2,816
2,735
2,654
2,593
2,578
Return on Invested Capital (%)
21.29
10.18
5.46
5.23
3.26
3.95
4.29
5.43
- -
1.12
0.5
- -
- -
- -
Return on Capital (%)
23.06
9.64
5.12
4.98
3.38
3.92
3.61
4.14
- -
0.17
-0.69
- -
- -
- -
Return on Common Equity (%)
23.07
11.39
7.33
7.11
4.19
5.56
5.54
5.94
-4.12
0.66
-0.4
1.19
-0.77
-1.34

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
18
40
51
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
491
480
480
Market Capitalization
3,216
2,699
2,732

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,057
1,001
999
Cash, Cash Equivalents & STI
536
482
465
Accounts Receivable, Net
208
198
219
Inventories
227
238
216
Total Current Liabilities
215
196
191
Payables & Accruals
- -
- -
- -
ST Debt
18
40
51
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.26%
-4.47%
-2.3%
Free Cash Flow
9.82%
-128.18%
-49.33%
Net Income, GAAP
-89.14%
-200.13%
-163.62%
Sales/Revenue/Turnover
7.46%
-13.36%
0.73%
Total Cash Common Dividend
9.34%
-1.89%
42.09%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
199
198
211
218
826
2025
202
213
- -
219
832
2026
213
184
211
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.05
- -
-0.02
0.06
2025
0.01
0.02
- -
-0.08
-0.04
2026
0.03
-0.04
0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.01
0.07
2025
- -
- -
- -
- -
0.1
2026
- -
- -
0.01
- -
- -

Company Description

CEO
De Rong Zhou
Full Time Employees
1,106
Sector
Health technology
Industry
Biotechnology
Address
No. 8, Pingbei 1st Road Zhuhai GD China 519060
IPO Date
Jan 28, 2014
Business
Guangdong VTR Bio-Tech Co., Ltd. is a biotechnology company primarily engaged in the research, development, production, sales, and service of biological enzyme preparations, biosynthetic products, and plant extracts. Its main products include feed enzymes (such as phytase, protease, xylanase, and Macleaya cordata extract), energy enzymes, washing enzymes, food enzymes, papermaking enzymes, textile enzymes, and various active natural products. The company also produces veterinary active pharmaceutical ingredients and formulations, along with botanical extracts like rosemary, echinacea, and verbena. Founded in 1991 and headquartered in Zhuhai, Guangdong Province, China, VTR Bio-Tech operates across multiple industries including agriculture and animal husbandry, biomanufacturing, and biomedical sectors with a significant presence both domestically and internationally. Recently, VTR Bio-Tech has undertaken several major initiatives reflecting its strategic focus on innovation and sustainable growth. The company opened a new R&D office building in Changsha in 2025, expanded its intelligent factory and National Enterprise Technology Center in Zhuhai, and held a major new product launch event in 2024 unveiling Yiduozyme, a next-generation xylanase, and the Yibeijia Com Series, a versatile detergent enzyme solution. VTR Bio-Tech has also accelerated its internationalization strategy, showcasing cutting-edge animal feed enzyme solutions at industry events such as VIV Asia 2025 and forming strategic partnerships to enhance its global market presence. These developments underline its commitment to advancing sustainable biotechnology and delivering efficient, high-performance bio-solutions to global customers. VTR Bio-Tech serves a diversified customer base in sectors including animal feed, agriculture, industrial biotechnology, and pharmaceutical research, targeting markets in China, Southeast Asia, and beyond. The company’s comprehensive biotechnology solutions focus on improving feed efficiency, reducing production costs, and promoting greener production processes. Its strategic emphasis remains on innovation-driven growth and expanding its product portfolio to meet evolving market demands worldwide.